Skip to main content

IBA SA – Update following capital increase dated 03 December 2019

Written by Customer Service on . Posted in Public Companies.

IBA – DATA CONCERNING TRANSPARENCY
Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008Louvain-la-Neuve, Belgium, December 03, 2019 – IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises of stock options) dated December 03, 2019.Communication of the basic data as per Article 15 §1 al.1 of the LawTotal capital: EUR 42 294 182,30 Total number of securities conferring the voting right: 30 133 920Total number of voting rights (= the denominator): 30 133 920Total number of securities conferring the voting right, by category: N/ATotal number of voting rights, by category: N/ACommunication of the additional data as per Article 15 §1 al.2 of the LawTotal number of convertible bonds conferring the voting right: 0Total number of rights, materialized or not by certificates, giving the
right to subscribe to newly issued securities conferring the voting right
(e.g. warrants): 187 108Total number of voting rights which would result from the exercise of
these conversion or subscription rights: 187 108Total number of shares without voting right: 0Statutory thresholds as per Article 18 of the LawThe applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percentAbout IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.comFor further information, please contact:IBA
Elodie Jaumain
Paralegal
+32 10 203 180
elodie.jaumain@iba-group.comAttachment20191203EvolutionofthebasicdataEN

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.